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Abstract: The E2F transcription factor family is traditionally associated with cell cycle 
control. However, recent data has shown that activating E2Fs (E2F1-3a) are potent 
activators of apoptosis. In contrast, the recently cloned inhibitory E2Fs (E2F7 and 8) 
appear to antagonize E2F-induced cell death. In this review we will discuss (i) the potential 
role of E2Fs in UV-induced cell death and (ii) the implications of this to the development 
of UV-induced cutaneous malignancies. 
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1. What is UV? 
Life on earth is dependent upon UV radiation as an energy source. Ironically, whilst humans are 
dependent upon UV radiation for their existence, UV radiation is a common and potent carcinogen for 
people of Caucasian descent [1].  
Ultraviolet (beyond violet) refers to wavelengths shorter than visible violet light and longer than  
X-rays [2]. The UV radiation spectrum is grouped into three categories based on wavelength. UVC 
(200–280 nm) is the most potent carcinogenic band of UV but poses little threat to terrestrial 
organisms since it is almost completely absorbed by the earth’s atmosphere. Only 10% of incident 
UVB (280–320 nm) radiation penetrates the atmosphere. The vast majority of incident UV (greater 
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than 90%) radiation comes from UVA (320–400 nm). Although UVA radiation predominates at sea 
level, UVB has the highest energy and is 1,000 times more erythematogenic than UVA [2]. Thus, the 
carcinogenic potential of the UV spectrum reaching the earth’s surface is a composite of a small 
amount of high energy UVB and a large amount of low energy UVA. Combined, UVA and UVB 
radiation damage DNA, disrupt pro-apoptotic signaling pathways and suppress immune responses 
ultimately contributing to the carcinogenic action of sunlight [3]. Despite the more potent carcinogenic 
activity of UVB it is only capable of penetrating the more superficial epidermal layers whereas UVA 
can penetrate deeper into the dermis [2].  
2. Mutagenic Effects of UV Radiation 
UV light is a physical mutagen and can ionize molecules resulting in the conversion of absorbed 
light energy into biochemical reactions. DNA is one of the major molecules capable of absorbing UV 
radiation. Absorbed UV radiation causes DNA damage via the formation of DNA lesions often 
referred to as photolesions [4]. DNA damage caused by UVA and UVB can be direct or indirect. 
Direct absorption of UVB by DNA results in the formation of photolesions such as cyclo-butane-
pyrimidine dimers (CPDs) and pyrimidine (6–4) pyrimidone dimers [5] (Table 1). If these pyrimidine 
dimers are not repaired by DNA repair mechanisms, it may result in heritable base transitions. 
Formation of these, C→T single or CC→TT double, transitions at dipyrimidine sites is mutagenic and 
the nature and the presence of these lesions are frequently referred to as the UVB signature [6]. On the 
other hand, UVA is not absorbed by DNA and causes DNA damage via an indirect mechanism 
involving the generation of reactive oxygen species (ROS) generated by UVA-mediated activation of 
photosensitizers (e.g., riboflavin, porphyrins, quinines) resulting in the accumulation of CPDs [7]. 
UVB may also cause the accumulation of ROS and hence can also facilitate indirect DNA damage, 
albeit to a lesser extent than observed with UVA [8] (Table 1).  
Table 1. Summary of mutagenic effects of UVA and UVB. 
 UVA UVB 
Wavelength (nm) 320–400 280–320 
Chromophores Photosensitizers DNA 
Site of damage ROS Pyrimidine dimers (CDP) 6–4 photoproducts 
Mechanism Indirect Direct 
3. Sunburn Cells (UV-Induced Cell Death) 
Following UV exposure keratinocytes will follow one of two fates. If the damage to DNA is 
perceived to be reparable, the keratinocytes will undergo a reversible growth arrest accompanied by 
the mobilisation and activation of the nucleotide excision repair system (NER). This leads to the repair 
of damaged DNA (mutations/DNA lesions) and is facilitated by secreted cytokines, IL12 and IL18, 
which can restore immune responses and prevent from UV-induced immunosuppression [9–11]. 
Alternatively, if the DNA damage is perceived to be too great and the cells lack the capacity to repair 
the damage then the cells will be induced to apoptose [12,13]. Apoptosis, or programmed cell death, is 
a mechanism that prevents cells from passing on mutated DNA to their progeny. Thus, the apoptotic 
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machinery provides a means by which mutated, potentially premalignant cells are able to be  
eliminated [14]. UV-induced apoptosis results in the formation of so-called “sunburn cells” or 
apoptotic keratinocytes. Sunburn cells are easily identified by the presence of photo lesions, pyknotic 
nuclei and cytoplasmic shrinkage characteristic of apoptotic cells [15]. UV-induced apoptotic 
responses are mediated via extrinsic/death receptor signaling and intrinsic/mitochondrial death 
pathways [11,16]. The extrinsic death pathway is initiated by the binding of membrane death receptors 
TNF-R1, CD95, TRAIL-R1 and TRAIL-R2 to their cognate ligands, TNF-α, CD95L/FASL or TRAIL 
(TNF-related apoptosis-inducing ligand). UV can also activate CD95 death receptor signaling 
pathways independent of its natural ligand CD95L [17]. The subsequent formation of a death-inducing 
signaling complex (DISC) is characteristic of death receptor-mediated apoptosis in response to UV 
radiation [18,19]. Activation of death receptor signaling ultimately activates the initiator pro-caspases-
8/-10 leading to the eventual activation of downstream effector procaspases-3,-6,-7 [12]. Activation of 
the intrinsic apoptotic pathway is stimulated by the release of cytochrome c from outer mitochondrial 
membrane [20]. Activation of the intrinsic apoptotic pathway is controlled by the balance between  
pro-apoptotic (Bax, Bak, Bad, Bid, Bim) and anti-apoptotic (Bcl-2, Bcl-Xl, Mcl-Xl) Bcl-2 family 
proteins. When pro-apoptotic stimuli predominate, it leads to the permeabilisation of the mitochondrial 
outer membrane potential leading to cytochrome C release and eventual procaspase-9 activation [21,22] 
(Figure 1).  
Figure 1. UV-mediated keratinocyte apoptosis can be initiated by extrinsic or intrinsic 
pathways. Extrinsic pathways include death receptor activation via death ligand binding, 
DISC formation, activation of pro-caspases and activation of effector caspase-3 leading to 
apoptosis. Activation of intrinsic pathways induces cytochrome c release from mitochondria 
and activation of pro-apoptotic Bcl-2 proteins and inhibition of anti-apoptotic Bcl-2 proteins, 
activation of pro-caspase-9 and activation of effector caspase-3 leading to apoptosis. 
 
4. Role of UV in Skin Carcinogenesis 
Skin cancers are frequently divided into melanoma and non-melanoma skin cancers (NMSC). 
Regardless of classification, the main contributory factor in the development of cutaneous malignancies, 
in humans, is UV exposure [23]. Melanoma is a common and aggressive tumour type derived from 
melanocytes. The major forms of non-melanoma skin cancer are basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) [24]. In a recent study, Trakatelli et al. [25] showed that NMSC had 
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significantly increased in incidence in Caucasians in the last decade. NMSC skin cancers are the most 
common malignancy in Caucasians and their incidence reflects the potent carcinogenic activity of UV 
radiation [26]. There are a number of reviews on the molecular mechanisms associated with  
UV-induced skin cancer and in particular we refer the reader to other articles within this issue of the 
journal. Of relevance to the current review are reports that UV-induced SCC formation is associated 
with dysregulation of the control of proliferation, differentiation and apoptosis [27–31]. Amongst these 
known changes it is notable that disruption of the Rb/E2F axis is over-represented. In particular, there 
is considerable data relating to the expression, activity and role of dysregulated E2F1 in SCC 
formation [26,32–35]. For example, disruption of the Rb/E2F axis is common in almost all human 
cancers including SCC [36]. Loss of function mutations of p53, Rb, or upstream regulators of the 
Rb/E2F axis such as INK4A (p16) are frequently associated with SCC and may result from mutation, 
deletion or promoter hypermethylation [37–39]. Moreover, SCCs are frequently associated with 
amplification/activation of mitogenic pathways controlled by cyclin D1, cdk4 or EGFR [31,40]. All 
these events are known to contribute to the dysregulation of proliferation and differentiation [31,40,41]. 
In addition, dysregulation of enzymes regulating oxidative stress such as GPX2 have also been shown 
to contribute casually to UV-induced SCC formation [25]. Dysregulation of antioxidant enzymes is 
known to disturb the apoptotic axis. Indeed, apoptotic regulators related to sensitivity and response to 
UV-induced damage are invariably targeted during keratinocyte transformation [13]. Consequently, 
the major safeguard that keratinocytes use to protect themselves against UV-induced mutations, 
namely sunburn cell formation, is compromised in keratinocytes following exposure to carcinogenic 
doses of UV [41]. However, the exact mechanisms by which UV-induced mutational damage contributes 
to the biological events controlling keratinocyte transformation and SCC progression remain unclear.  
5. The E2F Family 
The squamous differentiation program of the epidermis involves co-ordinate regulation of 
proliferation, differentiation and apoptosis. The barrier functions of the epidermis depend upon the 
integrity of this program and its ability to respond to environmental insults such as UV radiation [7,42]. 
The process of squamous differentiation is a tightly regulated process in which transcription factors 
control the differentiation program and its barrier functions [36]. Thus, it is not surprising that 
disruption to transcriptional control is a frequent target in oncogenesis [43]. Many transcription factors 
have been implicated in the control of squamous differentiation and carcinogenesis. However, the E2F 
family of transcription factors have emerged as pleiotropic regulators, directly controlling (i) cell 
proliferation, (ii) apoptosis, (iii) differentiation, (iv) DNA-damage response and DNA repair,  
(v) development, (vi) senescence and (vii) autophagy [28,29,44–49]. Moreover, E2Fs are also 
indirectly involved in modulating the activity of important cellular signaling pathways such as MAPK, 
p38 and PI3-K/AKT through transcriptional regulation of upstream pathway components [50,51]. 
E2F was first discovered as a cellular factor required for the activation of the E2 viral  
promoter [29,52]. This factor was later cloned and named E2F1 [43]. However, it was quickly 
recognised that E2F1 was just one member of, what is now, a family of 8 members, E2Fs 1–8, coding 
for 10 different E2F forms [53]. The role of the E2Fs is complex. Individual E2F family members can 
be involved in multiple cellular activities. For example, E2F1 is directly involved in the G1/S transition 
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(E2F3b-5) and inhibitory E2Fs (E2F6-E2F8). The expression of activator E2Fs varies during the cell 
cycle reaching a peak of activity, bound to target gene promoters via E2F response elements, during 
late G1/S phase. In this context, they control the expression of genes and activities required for DNA 
synthesis [53,67,68]. The expression and activity of the repressor E2Fs (E2F3b, E2F4, E2F5, E2F6) 
remain relatively constant throughout the cell cycle [53]. They bind target gene promoters during G0 
with E2F inhibitory pocket proteins coupled with repressive histone deacetylases [39,69] and prevent 
promiscuous transcription of proliferation genes [53,57,70]. The so-called repressor E2Fs get their 
name due to their ability to actively recruit transcriptional inhibitors such as histone deacetylase 1 (e.g., 
E2F4 and 5) or PRC2 (E2F6) to the E2F sites resulting in transcriptional repression [57,58].  
In contrast, inhibitory E2Fs (E2F 7 and 8) compete for binding sites with other E2Fs and mediate their 
inhibition by excluding active or repressive E2Fs from binding [55]. The expression of E2F7 and E2F8 
is cell-cycle regulated. Transcription of E2F7 and E2F8 increases towards G1-to-S transition reaching 
its peak during S-to-G2 transition [28,57,59,60,71]. Thus, the role of E2F7/8 in cell cycle control 
appears to tie in with the direct inhibition of the E2F1 activities related to cell cycle traverse [42,63].  
In contrast, the role of the inhibitory E2Fs in the control of differentiation appears to be isoform-specific 
and is mediated via isoform-specific DNA response elements [26,54]. Finally, the anti-apoptotic action 
of the inhibitory E2Fs appears to be mediated via direct inhibition of E2F1-mediated apoptosis [42,63]. 
The interplay between E2F1-stimulated apoptosis and E2F7/8-mediated inhibition of apoptosis is 
critical to understanding the role of E2Fs in UV-induced skin cancer formation and their potential as 
drugable targets for treating squamous cell carcinomas or enhancing chemotherapeutic responses. 
6. E2F-Induced Apoptosis and Skin Cancer Formation 
The ability of the different E2Fs to contribute to apoptosis especially to UV-mediated apoptosis is 
contentious. Much of this controversy arises from some seemingly paradoxical data relating to  
the action of E2F1. Earlier studies with E2F1 reported that overexpression of E2F1 in tissue culture 
cells and in transgenic mice caused a stimulation of apoptosis and an enhancement of tumour 
formation [33,34,72,73]. In particular, overexpression of E2F1 in the epidermis of transgenic mice 
caused elevated apoptotic indices in keratinocytes of the basal layer and an increase in skin tumour 
formation in mice that overexpressed E2F1 and cyclin D1 [34]. In contrast, mice transgenic for E2F4 
expression in skin did not have increased apoptotic indices [74]. Similarly, mice deficient for  
E2F1 were predisposed to thymomas due to their inability to delete t cells via E2F1-mediated 
apoptosis [75,76]. These earlier studies clearly supported the concept that the pro-proliferative actions 
of E2F1 were oncogenic whilst the pro-apoptotic actions of E2F1 were tumour suppressive [77].  
E2F1-stimulated apoptosis can be mediated by p53-dependent and p53-independent pathways. The 
p53-dependent pathway involves the stabilization of p53 via p14/p19ARF [78] whilst activation of 
APAF1 and p73 or CHK2 is required for p53-independent apoptosis [79–81]. In response to UV, E2F1 
transcript and protein levels increase in an ATM/ATR dependent manner and leads to accumulation of 
events required for apoptosis [82]. This suggested that UV-induced E2F1 mediated apoptosis in skin 
may have tumour suppressive effects. However, studies by Dimova and Dyson reported that the 
ectopic expression of E2F1 may result in the expression of survival genes suggesting that E2F1 may be 
anti-apoptotic under certain conditions [48]. This suggests that the role of E2F1 in regulating apoptosis 
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may be context-specific. Consistent with this, it has been reported that E2F1 is anti-apoptotic in 
keratinocytes in the context of UVB irradiation [52,83]. Specifically, E2F1 deficient mice and mice 
transgenic for E2F1 in skin displayed increased and reduced apoptotic indices in response to UVB 
irradiation respectively [52,78]. Wikonkal et al. [52] also showed that the pro-survival effect of E2F1, 
in response to UVB, was p53-independent. Finally, it was shown that the pro-survival effect of E2F1, 
in response to UVB irradiation of keratinocytes/epidermis could be attributed to the ability of E2F1 to 
sense DNA damage and co-ordinate the DNA damage repair [52]. In this regard, E2F1 has been 
reported to function directly at sites of DNA repair to eliminate DNA photoproducts [84,85] or 
indirectly by controlling the transcription of genes required for DNA repair machinery [86,87].  
Whilst these data appear to definitively show that E2F1 is oncogenic in skin due to its anti-apoptotic 
effects, there still remain some unresolved issues. For example, studies have shown that E2F1-mediated 
responses to UVB irradiation may be dose-dependent such that low doses of UVB activate DNA repair 
mechanisms whilst high doses induce apoptosis in cells in which the cellular DNA repair machinery is 
unable to repair the damage [88]. Moreover, another important consideration is the level of E2F1. For 
example, it is easy to see the benefit of a pro-survival signal being generated in response to the 
relatively low levels of E2F1 that may be experienced during cell cycle traverse. It is also easy to see 
biological justification that elevation of E2F1, in response to stressors such as UVB, could invoke 
apoptotic responses [89,90]. Earlier studies by Yang and his colleagues have shown that E2F6 is able 
to repress UV-induced apoptosis in human embryonic kidney cells via direct interaction with  
BRCA1 [91]. Intriguingly, the expression of E2F6 is influenced by E2F1 [92]. However, it is 
noteworthy that keratinocytes do not appear to express detectable levels of E2F6 [51] suggesting this 
situation may not apply in skin. The same cannot be said for recent studies with E2F7 and E2F8. E2F7 
and 8 are inhibitory E2Fs that bind to, and repress, E2F1 transcription and E2F1-induced  
apoptosis [63]. Both E2F7 and E2F8 are expressed in skin [57,61] and are able to influence the cellular 
DNA damage response [41]. Zalmas et al. [41] demonstrated that DNA damage induced by etoposide 
treatment induced E2F7 and E2F8 expression. Moreover, they demonstrated that DNA damage 
invoked an increase in E2F7 and E2F8 binding to E2F-responsive genes such as E2F1 resulting in an 
inhibition of E2F1-mediated apoptosis [41]. In fact, microarray analysis of cells subjected to DNA 
damage revealed that E2F7 and E2F8 could be considered bona fide DNA damage response  
genes [58,63] (Figure 3). These studies seem to be relevant to skin UV responses since we recently 
reported that E2F7 plays a role in regulating proliferation, differentiation and UV-induced cytotoxicity 
in human keratinocytes in vitro [26]. Moreover, we reported that E2F1 and E2F7 were overexpressed 
in human squamous cell carcinomas approximately 50 fold and 200 fold respectively [26]. Such 
elevations in E2F1 and E2F7 are clearly pathologic and the consequences on UV-induced tumour 
development and progression remain unknown. However, given that E2F1 and E2F7 are said to 
autoregulate the expression of one another and given that E2F7 antagonises E2F1-induced apoptosis 
and UV-induced apoptosis in human keratinocytes [26], it would seem reasonable to speculate that 
E2F7 may also play a role in UV responses in human epidermis (Figure 4). Thus, apoptotic responses 
of keratinocytes, to UV, or chemotherapeutics, are likely to be dictated by the relative levels of E2F1 
and E2F7. 
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In conclusion, the carcinogenic components of sunlight, relevant to humans, are UVA and UVB. 
UV radiation induces either a cell cycle arrest or an apoptotic response in human keratinocytes. Both 
the cell cycle arrest and the apoptotic response appear to be mediated by E2F1. More recently, an 
antagonistic form of E2F, E2F7, has been reported that antagonizes the pro-proliferative and apoptotic 
effects of E2F1. Both E2F1 and E2F7 are significantly overexpressed in transformed keratinocytes and 
there is evidence that the dysregulation of expression of the E2F1 and E2F7 isoforms may contribute 
to skin cancer formation. 
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